Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vaccitech Plc ADR (NQ: VACC )

1.670 -0.010 (-0.60%)
Streaming Delayed Price Updated: 11:07 AM EDT, Sep 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,020
Open 1.670
Bid (Size) 1.660 (1)
Ask (Size) 1.670 (1)
Prev. Close 1.680
Today's Range 1.670 - 1.670
52wk Range 1.663 - 3.360
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023
From Vaccitech plc
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
  Monday's session saw 175 companies set new 52-week lows. 
Via Benzinga

Performance

YTD
-30.42%
-30.42%
1 Month
-16.08%
-16.08%
3 Month
-26.75%
-26.75%
6 Month
-39.49%
-39.49%
1 Year
-48.77%
-48.77%

More News

Read More
Analyst Expectations for Vaccitech's Future
Via Benzinga
Vaccitech: Q1 Earnings Insights
Via Benzinga
Vaccitech Earnings Perspective: Return On Capital Employed
Via Benzinga
A Look Into Healthcare Sector Value Stocks
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Overview Of Value Stocks In The Healthcare Sector
Via Benzinga
Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
From Vaccitech plc
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B
From Vaccitech plc
Via GlobeNewswire
Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody
From Arbutus Biopharma Corporation
Via GlobeNewswire
Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy
From Vaccitech plc
Via GlobeNewswire
Over $4M Bet On Diversified Healthcare Trust? Check Out These 4 Stocks Under $5 Insiders Are Aggressively Buying
Via Benzinga
Vaccitech Presents Interim Data from Phase 1b/2 Study of VTP-200 at 35th Annual International Papillomavirus Conference (IPVC) Highlighting Favorable Tolerability and Immunogenicity Profile
From Vaccitech plc
Via GlobeNewswire
7 Thrilling Biotech Stocks for Aggressive Investors to Buy
Via InvestorPlace
Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B
From Vaccitech plc
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Scholastic Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Crude Oil Down 1%; US Composite PMI Jumps In March
Via Benzinga
Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments
From Vaccitech plc
Via GlobeNewswire
Why Block Shares Are Trading Lower By Over 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Vaccitech’s VTP-200 Ph 1b/2 Study Demonstrates Favorable Tolerability and Immunogenicity Profile at Interim Analysis in Women with Low-Grade Human Papillomavirus (HPV)-related Cervical Lesions
From Vaccitech plc
Via GlobeNewswire
Vaccitech Appoints Industry Veteran, Nadège Pelletier, Ph.D., as Chief Scientific Officer
From Vaccitech plc
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.